Immune-Boosting drug could help fight High-Risk thyroid cancer before surgery

NCT ID NCT05852223

Recruiting now Disease control Sponsor: Istituti Clinici Scientifici Maugeri SpA Source: ClinicalTrials.gov ↗

First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This phase 2 trial is testing whether giving the drug pembrolizumab before thyroid surgery can help the immune system attack high-risk differentiated thyroid cancer. About 25 adults with a high chance of cancer returning will receive two doses of pembrolizumab before their thyroidectomy. Researchers will study immune cells in the tumor and blood to see how the drug works.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: Pembrolizumab (a drug that helps the immune system fight cancer)
What this could lead to: If it works, this could point toward a new treatment option for high-risk thyroid cancer before surgery.
What could go wrong: This is a small, early-phase trial with only 25 participants, so results may not apply to everyone. The drug may not shrink tumors or could cause immune-related side effects.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for DIFFERENTIATED THYROID CANCER are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

differentiated thyroid carcinoma poorly differentiated thyroid gland carcinoma thyroid Hurthle cell carcinoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

DIFFERENTIATED THYROID CANCER

Contacts and locations

Locations

Istituti Clinici Scientifici Maugeri
RECRUITING

Pavia, Lombardy, 27100, Italy

More trials for these conditions

Other studies related to the condition(s) this trial covers.